GleamWall
中文EN

EOCN EoCene Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4.87M$2.98M
SG&A expense$3.64M$3.30M
Pretax income—$7.52M
Income tax$0—
Net income-$10.31M-$7.52M
EPS (basic)2.398.08
EPS (diluted)2.398.08
Weighted avg. shares (diluted)4.31M930,822
Balance sheet
Cash & equivalents$3.98M$4.65M
Short-term investments$7.03M$7.18M
Receivables—$672,000
Current assets$18.63M$16.12M
Total assets$18.63M$18.50M
Current liabilities$2.85M$2.17M
Total liabilities$2.85M$2.17M
Shareholders' equity$15.78M$16.33M
Shares outstanding822,6741.66M
Cash flow statement
Operating cash flow-$6.32M-$5.88M
Investing cash flow-$3.38M-$1.11M
Financing cash flow$9.03M$8.79M
Depreciation & amortization—$83,000
Stock-based compensation$546,000$531,000

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.